Valuation: UCB SA

Market Cap 38.3B 42.94B 35.69B 32.48B 61.16B 4,135B 61.61B 431B 168B 2,111B 161B 158B 6,784B P/E 2026 *
20.1x
P/E 2027 * 16.7x
Enterprise Value 38.72B 43.4B 36.07B 32.83B 61.82B 4,180B 62.27B 436B 170B 2,133B 163B 159B 6,857B EV / Sales 2026 *
4.47x
EV / Sales 2027 * 3.81x
Free-Float
61.59%
Yield 2026 *
0.72%
Yield 2027 * 0.75%
Manager TitleAgeSince
Chief Executive Officer 67 01/01/2015
Director of Finance/CFO 60 01/07/2020
Chief Tech/Sci/R&D Officer 59 01/05/2024
Director TitleAgeSince
Director/Board Member 55 01/01/2012
Director/Board Member 67 01/01/2015
Director/Board Member 56 24/04/2014
Change 5-day change 1-year change 3-year change Capi.($)
+4.76%+29.83% - - 43.84B
+0.02%-3.52%+36.11%+111.11% 1,019B
-1.21%-6.99%+34.08%+60.96% 617B
+1.12%-0.20%+13.62%+80.24% 464B
-3.30%-6.15%+56.45%+34.69% 356B
+0.93%-3.16%+21.65%+43.02% 333B
+0.12%-2.77%+10.70%+32.97% 267B
-0.89%-6.28%-7.00%+8.01% 244B
-0.01%-3.62%+35.28%+52.02% 218B
-0.08%-4.98%+28.34%+93.61% 179B
Average +0.67%-3.54%+25.47%+57.40% 410.8B
Weighted average by Cap. +0.49%-3.54%+28.50%+68.60%

Financials

2026 *2027 *
Net sales 8.66B 9.71B 8.07B 7.34B 13.83B 935B 13.93B 97.48B 37.92B 477B 36.44B 35.65B 1,534B 9.61B 10.77B 8.95B 8.14B 15.34B 1,037B 15.45B 108B 42.07B 529B 40.42B 39.55B 1,701B
Net income 1.93B 2.16B 1.8B 1.63B 3.08B 208B 3.1B 21.7B 8.44B 106B 8.11B 7.94B 341B 2.3B 2.57B 2.14B 1.95B 3.67B 248B 3.69B 25.86B 10.06B 127B 9.67B 9.46B 407B
Net Debt 413M 463M 384M 350M 659M 44.55B 664M 4.65B 1.81B 22.74B 1.74B 1.7B 73.09B -1.7B -1.9B -1.58B -1.44B -2.71B -183B -2.73B -19.08B -7.42B -93.39B -7.13B -6.98B -300B
Logo UCB SA
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Trader
Investor
Global
Quality
ESG MSCI
AA